MIRA Pharmaceuticals, Inc.
MIRA
$0.96
-$0.01-1.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 5.33M | 904.30K | 1.05M | 1.49M | 1.58M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.82M | 1.32M | 1.55M | 1.81M | 2.44M |
| Operating Income | -5.82M | -1.32M | -1.55M | -1.81M | -2.44M |
| Income Before Tax | -5.98M | -1.14M | -1.54M | -1.78M | -2.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -5.98M | -1.14M | -1.54M | -1.78M | -2.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.98M | -1.14M | -1.54M | -1.78M | -2.40M |
| EBIT | -5.82M | -1.32M | -1.55M | -1.81M | -2.44M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.15 | -1.18 | -0.09 | -0.11 | -0.14 |
| Normalized Basic EPS | -0.09 | -0.04 | -0.06 | -0.07 | -0.09 |
| EPS Diluted | -0.15 | -1.18 | -0.09 | -0.11 | -0.14 |
| Normalized Diluted EPS | -0.09 | -0.04 | -0.06 | -0.07 | -0.09 |
| Average Basic Shares Outstanding | 40.82M | 19.27M | 16.99M | 16.65M | 16.56M |
| Average Diluted Shares Outstanding | 40.82M | 19.27M | 16.99M | 16.65M | 16.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |